Literature DB >> 8511496

Efficacy of twice daily doses of 40 or 20 milligrams famotidine or 150 milligrams ranitidine for treatment of patients with moderate to severe erosive esophagitis. Famotidine Erosive Esophagitis Study Group.

T J Simon1, R G Berlin, R Tipping, L Gilde.   

Abstract

The comparative efficacy of twice daily regimens of 40 mg famotidine (group 1), 20 mg famotidine (group 2), and 150 mg ranitidine (group 3) was investigated in a double-blind randomized study of parallel groups of patients with endoscopically documented erosive esophagitis. Patients were enrolled at 29 centers in 19 countries and treated for 6 to 12 weeks until healing, defined as complete resolution of visible ulceration or erosion of the esophageal mucosa, demonstrated by repeat endoscopy. Healing occurred in 71% of 175 group-1 patients, 68% of 93 group-2 patients, and 60% of 172 group-3 patients; the difference between groups 1 and 3 was significant (P < or = 0.05). The three treatments produced similar levels of global symptomatic improvement and relief of daytime and nighttime heartburn. All treatments were well tolerated. These results support the hypothesis that reduction of esophageal acid exposure by 40 mg famotidine twice daily produces healing of lesions in patients with erosive esophagitis and is more effective than regimens that provide lesser reductions in esophageal acid exposure time.

Entities:  

Mesh:

Substances:

Year:  1993        PMID: 8511496     DOI: 10.3109/00365529309098235

Source DB:  PubMed          Journal:  Scand J Gastroenterol        ISSN: 0036-5521            Impact factor:   2.423


  7 in total

1.  Head-to-head comparison of H2-receptor antagonists and proton pump inhibitors in the treatment of erosive esophagitis: a meta-analysis.

Authors:  Wei-Hong Wang; Jia-Qing Huang; Ge-Fan Zheng; Harry Hua-Xiang Xia; Wai-Man Wong; Shiu-Kum Lam; Benjamin Chun-Yu Wong
Journal:  World J Gastroenterol       Date:  2005-07-14       Impact factor: 5.742

Review 2.  Ranitidine: a pharmacoeconomic evaluation of its use in acid-related disorders.

Authors:  J E Frampton; D McTavish
Journal:  Pharmacoeconomics       Date:  1994-07       Impact factor: 4.981

Review 3.  Formulary management of drugs for cancer-associated hypercalcaemia.

Authors:  S J Gallacher
Journal:  Pharmacoeconomics       Date:  1996-01       Impact factor: 4.981

4.  Switching the histamine H2 receptor antagonist famotidine to nonprescription status in Canada. An economic evaluation.

Authors:  R F Tasch; R Goeree; C J Henke; B J O'Brien
Journal:  Pharmacoeconomics       Date:  1996-01       Impact factor: 4.981

5.  Economic evaluation of long-term management strategies for erosive oesophagitis.

Authors:  R Goeree; B O'Brien; R Hunt; G Blackhouse; A Willan; J Watson
Journal:  Pharmacoeconomics       Date:  1999-12       Impact factor: 4.981

Review 6.  A systematic review of symptomatic outcomes used in oesophagitis drug therapy trials.

Authors:  N Sharma; C Donnellan; C Preston; B Delaney; G Duckett; P Moayyedi
Journal:  Gut       Date:  2004-05       Impact factor: 23.059

Review 7.  pH, healing rate, and symptom relief in patients with GERD.

Authors:  J Q Huang; R H Hunt
Journal:  Yale J Biol Med       Date:  1999 Mar-Jun
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.